Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin

Juan Fernando Gallegos-Orozco, Ana Paula Fuentes, Marco Antonio Olivera-Martinez, Gabriela Gutiérrez-Reyes, Diego Cortina, Jesús Alberto Oregel, Christian Pérez-Pruna, María Sara Sixtos, Socorro Cruz-Castellanos, Luis Enrique Soto-Ramírez, Roberto Rodríguez-Díaz, Luis Fuentes-Romero, María Concepción Gutiérrez-Ruiz, David Kershenobich

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Introduction. Currently, interferon alfa and ribavirin are the mainstay of therapy for patients with chronic hepatitis C. Recently the pegylation of interferon has allowed a once weekly application, resulting in an increased sustained viral response rate. The analysis of serum HCV dynamics has been shown to be useful in predicting clinical effects and optimizing the treatment regimen. Aim. The aim of the present study was to assess early serum HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b plus ribavirin. Methods. Male and female patients aged 18 to 65 years with chronic hepatitis C were eligible for the study. All patients received peginterferon alfa 2b 1.5 μg/kg once-weekly for 4 weeks and then peginterferon alfa 2b 0.5 μg/kg once-weekly until the completion of the 48 week trial period, plus ribavirin orally with meals, adjusted to body weight. HCV RNA was determined at base-line, 48 hours, 4 and 12 weeks of therapy. Results. Data were obtained from 20 patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin; 16 male, 4 female, with a mean age of 44.4 ± 11.9 years, 16 patients (80%) were infected with HCV genotype 1, the remainder were infected with genotype 2. Mean baseline HCV RNA for the total group was 1,091,405 ± 972,715 IU/mL. Mean reductions in viral load at 48 hours, 4 and 12 weeks for the 20 patients were 1.31 ± 0.91 log, 1.99 ± 1.27 log and 2.31 ± 1.25 log, respectively. A > 2 log reduction in HCV RNA was noticed in 12/20 patients (60%) at 4 weeks (early viral responders), in 9 of them (45%) HCV RNA was undetectable. This response in HCV RNA persisted at 12 weeks of therapy. Early viral responders had a significant reduction in HCV RNA at 48 hours after the initial peginterferon alfa 2b injection (> 1 log reduction). Early viral response was observed in 8/16 patients with HCV genotype 1, and in all genotype 2 patients. Conclusion. Treatment with peginterferon alfa 2b and ribavirin produces significant changes in the early HCV viral dynamics supporting the concept that such changes may be pivotal in achieving a sustained viral response.

Original languageEnglish (US)
Pages (from-to)138-142
Number of pages5
JournalRevista de Investigacion Clinica
Volume55
Issue number2
StatePublished - Mar 1 2003

Fingerprint

Ribavirin
Chronic Hepatitis C
RNA
Genotype
peginterferon alfa-2b
Therapeutics
Viral Load
Serum
Interferon-alpha
Interferons
Meals
Body Weight
Injections

Keywords

  • Chronic hepatitis C.
  • Early viral response
  • Hepatitis C virus
  • Peginterferon alfa 2b
  • Ribavirin
  • Serum HCV RNA

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Gallegos-Orozco, J. F., Fuentes, A. P., Olivera-Martinez, M. A., Gutiérrez-Reyes, G., Cortina, D., Oregel, J. A., ... Kershenobich, D. (2003). Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin. Revista de Investigacion Clinica, 55(2), 138-142.

Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin. / Gallegos-Orozco, Juan Fernando; Fuentes, Ana Paula; Olivera-Martinez, Marco Antonio; Gutiérrez-Reyes, Gabriela; Cortina, Diego; Oregel, Jesús Alberto; Pérez-Pruna, Christian; Sixtos, María Sara; Cruz-Castellanos, Socorro; Soto-Ramírez, Luis Enrique; Rodríguez-Díaz, Roberto; Fuentes-Romero, Luis; Gutiérrez-Ruiz, María Concepción; Kershenobich, David.

In: Revista de Investigacion Clinica, Vol. 55, No. 2, 01.03.2003, p. 138-142.

Research output: Contribution to journalArticle

Gallegos-Orozco, JF, Fuentes, AP, Olivera-Martinez, MA, Gutiérrez-Reyes, G, Cortina, D, Oregel, JA, Pérez-Pruna, C, Sixtos, MS, Cruz-Castellanos, S, Soto-Ramírez, LE, Rodríguez-Díaz, R, Fuentes-Romero, L, Gutiérrez-Ruiz, MC & Kershenobich, D 2003, 'Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin', Revista de Investigacion Clinica, vol. 55, no. 2, pp. 138-142.
Gallegos-Orozco JF, Fuentes AP, Olivera-Martinez MA, Gutiérrez-Reyes G, Cortina D, Oregel JA et al. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin. Revista de Investigacion Clinica. 2003 Mar 1;55(2):138-142.
Gallegos-Orozco, Juan Fernando ; Fuentes, Ana Paula ; Olivera-Martinez, Marco Antonio ; Gutiérrez-Reyes, Gabriela ; Cortina, Diego ; Oregel, Jesús Alberto ; Pérez-Pruna, Christian ; Sixtos, María Sara ; Cruz-Castellanos, Socorro ; Soto-Ramírez, Luis Enrique ; Rodríguez-Díaz, Roberto ; Fuentes-Romero, Luis ; Gutiérrez-Ruiz, María Concepción ; Kershenobich, David. / Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin. In: Revista de Investigacion Clinica. 2003 ; Vol. 55, No. 2. pp. 138-142.
@article{1cf52e4db51b422b80318223902e5da6,
title = "Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin",
abstract = "Introduction. Currently, interferon alfa and ribavirin are the mainstay of therapy for patients with chronic hepatitis C. Recently the pegylation of interferon has allowed a once weekly application, resulting in an increased sustained viral response rate. The analysis of serum HCV dynamics has been shown to be useful in predicting clinical effects and optimizing the treatment regimen. Aim. The aim of the present study was to assess early serum HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b plus ribavirin. Methods. Male and female patients aged 18 to 65 years with chronic hepatitis C were eligible for the study. All patients received peginterferon alfa 2b 1.5 μg/kg once-weekly for 4 weeks and then peginterferon alfa 2b 0.5 μg/kg once-weekly until the completion of the 48 week trial period, plus ribavirin orally with meals, adjusted to body weight. HCV RNA was determined at base-line, 48 hours, 4 and 12 weeks of therapy. Results. Data were obtained from 20 patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin; 16 male, 4 female, with a mean age of 44.4 ± 11.9 years, 16 patients (80{\%}) were infected with HCV genotype 1, the remainder were infected with genotype 2. Mean baseline HCV RNA for the total group was 1,091,405 ± 972,715 IU/mL. Mean reductions in viral load at 48 hours, 4 and 12 weeks for the 20 patients were 1.31 ± 0.91 log, 1.99 ± 1.27 log and 2.31 ± 1.25 log, respectively. A > 2 log reduction in HCV RNA was noticed in 12/20 patients (60{\%}) at 4 weeks (early viral responders), in 9 of them (45{\%}) HCV RNA was undetectable. This response in HCV RNA persisted at 12 weeks of therapy. Early viral responders had a significant reduction in HCV RNA at 48 hours after the initial peginterferon alfa 2b injection (> 1 log reduction). Early viral response was observed in 8/16 patients with HCV genotype 1, and in all genotype 2 patients. Conclusion. Treatment with peginterferon alfa 2b and ribavirin produces significant changes in the early HCV viral dynamics supporting the concept that such changes may be pivotal in achieving a sustained viral response.",
keywords = "Chronic hepatitis C., Early viral response, Hepatitis C virus, Peginterferon alfa 2b, Ribavirin, Serum HCV RNA",
author = "Gallegos-Orozco, {Juan Fernando} and Fuentes, {Ana Paula} and Olivera-Martinez, {Marco Antonio} and Gabriela Guti{\'e}rrez-Reyes and Diego Cortina and Oregel, {Jes{\'u}s Alberto} and Christian P{\'e}rez-Pruna and Sixtos, {Mar{\'i}a Sara} and Socorro Cruz-Castellanos and Soto-Ram{\'i}rez, {Luis Enrique} and Roberto Rodr{\'i}guez-D{\'i}az and Luis Fuentes-Romero and Guti{\'e}rrez-Ruiz, {Mar{\'i}a Concepci{\'o}n} and David Kershenobich",
year = "2003",
month = "3",
day = "1",
language = "English (US)",
volume = "55",
pages = "138--142",
journal = "Revista de Investigacion Clinica",
issn = "0034-8376",
publisher = "Instituto Nacional de la Nutricion Salvador Zubiran",
number = "2",

}

TY - JOUR

T1 - Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin

AU - Gallegos-Orozco, Juan Fernando

AU - Fuentes, Ana Paula

AU - Olivera-Martinez, Marco Antonio

AU - Gutiérrez-Reyes, Gabriela

AU - Cortina, Diego

AU - Oregel, Jesús Alberto

AU - Pérez-Pruna, Christian

AU - Sixtos, María Sara

AU - Cruz-Castellanos, Socorro

AU - Soto-Ramírez, Luis Enrique

AU - Rodríguez-Díaz, Roberto

AU - Fuentes-Romero, Luis

AU - Gutiérrez-Ruiz, María Concepción

AU - Kershenobich, David

PY - 2003/3/1

Y1 - 2003/3/1

N2 - Introduction. Currently, interferon alfa and ribavirin are the mainstay of therapy for patients with chronic hepatitis C. Recently the pegylation of interferon has allowed a once weekly application, resulting in an increased sustained viral response rate. The analysis of serum HCV dynamics has been shown to be useful in predicting clinical effects and optimizing the treatment regimen. Aim. The aim of the present study was to assess early serum HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b plus ribavirin. Methods. Male and female patients aged 18 to 65 years with chronic hepatitis C were eligible for the study. All patients received peginterferon alfa 2b 1.5 μg/kg once-weekly for 4 weeks and then peginterferon alfa 2b 0.5 μg/kg once-weekly until the completion of the 48 week trial period, plus ribavirin orally with meals, adjusted to body weight. HCV RNA was determined at base-line, 48 hours, 4 and 12 weeks of therapy. Results. Data were obtained from 20 patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin; 16 male, 4 female, with a mean age of 44.4 ± 11.9 years, 16 patients (80%) were infected with HCV genotype 1, the remainder were infected with genotype 2. Mean baseline HCV RNA for the total group was 1,091,405 ± 972,715 IU/mL. Mean reductions in viral load at 48 hours, 4 and 12 weeks for the 20 patients were 1.31 ± 0.91 log, 1.99 ± 1.27 log and 2.31 ± 1.25 log, respectively. A > 2 log reduction in HCV RNA was noticed in 12/20 patients (60%) at 4 weeks (early viral responders), in 9 of them (45%) HCV RNA was undetectable. This response in HCV RNA persisted at 12 weeks of therapy. Early viral responders had a significant reduction in HCV RNA at 48 hours after the initial peginterferon alfa 2b injection (> 1 log reduction). Early viral response was observed in 8/16 patients with HCV genotype 1, and in all genotype 2 patients. Conclusion. Treatment with peginterferon alfa 2b and ribavirin produces significant changes in the early HCV viral dynamics supporting the concept that such changes may be pivotal in achieving a sustained viral response.

AB - Introduction. Currently, interferon alfa and ribavirin are the mainstay of therapy for patients with chronic hepatitis C. Recently the pegylation of interferon has allowed a once weekly application, resulting in an increased sustained viral response rate. The analysis of serum HCV dynamics has been shown to be useful in predicting clinical effects and optimizing the treatment regimen. Aim. The aim of the present study was to assess early serum HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b plus ribavirin. Methods. Male and female patients aged 18 to 65 years with chronic hepatitis C were eligible for the study. All patients received peginterferon alfa 2b 1.5 μg/kg once-weekly for 4 weeks and then peginterferon alfa 2b 0.5 μg/kg once-weekly until the completion of the 48 week trial period, plus ribavirin orally with meals, adjusted to body weight. HCV RNA was determined at base-line, 48 hours, 4 and 12 weeks of therapy. Results. Data were obtained from 20 patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin; 16 male, 4 female, with a mean age of 44.4 ± 11.9 years, 16 patients (80%) were infected with HCV genotype 1, the remainder were infected with genotype 2. Mean baseline HCV RNA for the total group was 1,091,405 ± 972,715 IU/mL. Mean reductions in viral load at 48 hours, 4 and 12 weeks for the 20 patients were 1.31 ± 0.91 log, 1.99 ± 1.27 log and 2.31 ± 1.25 log, respectively. A > 2 log reduction in HCV RNA was noticed in 12/20 patients (60%) at 4 weeks (early viral responders), in 9 of them (45%) HCV RNA was undetectable. This response in HCV RNA persisted at 12 weeks of therapy. Early viral responders had a significant reduction in HCV RNA at 48 hours after the initial peginterferon alfa 2b injection (> 1 log reduction). Early viral response was observed in 8/16 patients with HCV genotype 1, and in all genotype 2 patients. Conclusion. Treatment with peginterferon alfa 2b and ribavirin produces significant changes in the early HCV viral dynamics supporting the concept that such changes may be pivotal in achieving a sustained viral response.

KW - Chronic hepatitis C.

KW - Early viral response

KW - Hepatitis C virus

KW - Peginterferon alfa 2b

KW - Ribavirin

KW - Serum HCV RNA

UR - http://www.scopus.com/inward/record.url?scp=0038724240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038724240&partnerID=8YFLogxK

M3 - Article

C2 - 12827916

AN - SCOPUS:0038724240

VL - 55

SP - 138

EP - 142

JO - Revista de Investigacion Clinica

JF - Revista de Investigacion Clinica

SN - 0034-8376

IS - 2

ER -